BAT2_MYCRK
ID BAT2_MYCRK Reviewed; 997 AA.
AC E5AW45;
DT 29-OCT-2014, integrated into UniProtKB/Swiss-Prot.
DT 08-FEB-2011, sequence version 1.
DT 25-MAY-2022, entry version 45.
DE RecName: Full=Burkholderia TALE-like protein 2 {ECO:0000303|PubMed:24792163};
DE AltName: Full=Modular DNA-binding domain protein BurrH2 {ECO:0000303|PubMed:24452192};
GN Name=bat2 {ECO:0000303|PubMed:24792163}; OrderedLocusNames=RBRH_01776;
OS Mycetohabitans rhizoxinica (strain DSM 19002 / CIP 109453 / HKI 454)
OS (Paraburkholderia rhizoxinica).
OG Plasmid pBRH02.
OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;
OC Burkholderiaceae; Mycetohabitans.
OX NCBI_TaxID=882378;
RN [1]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC STRAIN=DSM 19002 / CIP 109453 / HKI 454; PLASMID=pBRH02;
RX PubMed=21131495; DOI=10.1128/jb.01318-10;
RA Lackner G., Moebius N., Partida-Martinez L., Hertweck C.;
RT "Complete genome sequence of Burkholderia rhizoxinica, an endosymbiont of
RT Rhizopus microsporus.";
RL J. Bacteriol. 193:783-784(2011).
RN [2]
RP FUNCTION, DOMAIN, BIOTECHNOLOGY, REPEAT, AND DNA-BINDING.
RC STRAIN=DSM 19002 / CIP 109453 / HKI 454;
RX PubMed=24792163; DOI=10.1093/nar/gku329;
RA de Lange O., Wolf C., Dietze J., Elsaesser J., Morbitzer R., Lahaye T.;
RT "Programmable DNA-binding proteins from Burkholderia provide a fresh
RT perspective on the TALE-like repeat domain.";
RL Nucleic Acids Res. 42:7436-7449(2014).
RN [3]
RP BIOTECHNOLOGY USES REVIEW.
RX PubMed=24602153; DOI=10.1111/tpj.12431;
RA de Lange O., Binder A., Lahaye T.;
RT "From dead leaf, to new life: TAL effectors as tools for synthetic
RT biology.";
RL Plant J. 78:753-771(2014).
RN [4]
RP BIOTECHNOLOGY, DOMAIN, AND REPEAT.
RX PubMed=24452192; DOI=10.1038/srep03831;
RA Juillerat A., Bertonati C., Dubois G., Guyot V., Thomas S., Valton J.,
RA Beurdeley M., Silva G.H., Daboussi F., Duchateau P.;
RT "BurrH: a new modular DNA binding protein for genome engineering.";
RL Sci. Rep. 4:3831-3831(2014).
CC -!- FUNCTION: Binds to DNA in a sequence-specific manner.
CC {ECO:0000269|PubMed:24792163}.
CC -!- DOMAIN: The protein is composed of 27 tandem core repeats (the BuD
CC domain) with 1 base-specifying residue (BSR, residue 13), which
CC recognizes 1 base pair in the target DNA.
CC {ECO:0000250|UniProtKB:E5AV36}.
CC -!- BIOTECHNOLOGY: By combining the DNA-binding domain with the catalytic
CC domain of the restriction endonuclease FokI, TALE-nuclease (TALEN, or
CC BuDN) enzymes able to target specific dsDNA sequences can be created
CC that enable eukaryotic genome modification. Other potential uses as
CC transcriptional repressors, for transposon targeting, DNA methylation
CC or histone tail modifictions are also possible.
CC {ECO:0000303|PubMed:24452192, ECO:0000303|PubMed:24602153,
CC ECO:0000303|PubMed:24792163}.
CC -!- MISCELLANEOUS: DNA binding experiments were performed with a construct
CC missing repeat 11. {ECO:0000305}.
CC -!- SIMILARITY: Belongs to the transcription activator-like effector (TALE)
CC family. Bat subfamily. {ECO:0000303|PubMed:24792163}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; FR687361; CBW77347.1; -; Genomic_DNA.
DR AlphaFoldDB; E5AW45; -.
DR SMR; E5AW45; -.
DR EnsemblBacteria; CBW77347; CBW77347; RBRH_01776.
DR KEGG; brh:RBRH_01776; -.
DR HOGENOM; CLU_300299_0_0_4; -.
DR OMA; QATIVKI; -.
DR Proteomes; UP000007437; Plasmid pBRH02.
DR GO; GO:0003690; F:double-stranded DNA binding; IDA:UniProtKB.
DR InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR InterPro; IPR005042; TAL_effector_rpt.
DR Pfam; PF03377; TAL_effector; 28.
DR SUPFAM; SSF48403; SSF48403; 1.
DR PROSITE; PS50297; ANK_REP_REGION; 1.
PE 1: Evidence at protein level;
KW ANK repeat; DNA-binding; Plasmid; Reference proteome; Repeat.
FT CHAIN 1..997
FT /note="Burkholderia TALE-like protein 2"
FT /id="PRO_0000430624"
FT REPEAT 19..50
FT /note="Cryptic repeat -1"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 51..83
FT /note="Cryptic repeat 0"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 84..116
FT /note="Core repeat 1"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 117..147
FT /note="Core repeat 2"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 148..180
FT /note="Core repeat 3"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 181..213
FT /note="Core repeat 4"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 214..244
FT /note="Core repeat 5"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 245..277
FT /note="Core repeat 6"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 278..310
FT /note="Core repeat 7"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 311..343
FT /note="Core repeat 8"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 344..376
FT /note="Core repeat 9"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 377..409
FT /note="Core repeat 10"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 410..442
FT /note="Core repeat 11"
FT /evidence="ECO:0000303|PubMed:24452192, ECO:0000305"
FT REPEAT 443..475
FT /note="Core repeat 12"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 476..508
FT /note="Core repeat 13"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 509..539
FT /note="Core repeat 14"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 540..572
FT /note="Core repeat 15"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 573..605
FT /note="Core repeat 16"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 606..638
FT /note="Core repeat 17"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 639..671
FT /note="Core repeat 18"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 672..704
FT /note="Core repeat 19"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 705..737
FT /note="Core repeat 20"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 738..770
FT /note="Core repeat 21"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 771..803
FT /note="Core repeat 22"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 772..801
FT /note="ANK 1"
FT /evidence="ECO:0000255"
FT REPEAT 804..836
FT /note="Core repeat 23"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 805..834
FT /note="ANK 2"
FT /evidence="ECO:0000255"
FT REPEAT 837..869
FT /note="Core repeat 24"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 838..867
FT /note="ANK 3"
FT /evidence="ECO:0000255"
FT REPEAT 870..902
FT /note="Core repeat 25"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 871..900
FT /note="ANK 4"
FT /evidence="ECO:0000255"
FT REPEAT 903..935
FT /note="Core repeat 26"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 936..967
FT /note="Core repeat 27"
FT /evidence="ECO:0000303|PubMed:24452192,
FT ECO:0000303|PubMed:24792163"
FT REPEAT 968..997
FT /note="Cryptic repeat +1"
FT /evidence="ECO:0000303|PubMed:24792163"
FT REGION 84..967
FT /note="BuD domain"
FT /evidence="ECO:0000250|UniProtKB:E5AV36"
SQ SEQUENCE 997 AA; 104525 MW; 7EA4A989847799E7 CRC64;
MPATSMHQED KQSANGLNLS PLERIKIEKH YGGGATLAFI SNQHDELAQV LSRADILKIA
SYDCAAQALQ AVLDCGPMLG KRGFSRADIV RIAGNGGGAQ ALYSVLDVEP TLGKRGFSQV
DVVKIAGGGA QALHTVLEIG PTLGERGFSR GDIVTIAGNN GGAQALQAVL ELEPTLRERG
FNQADIVKIA GNGGGAQALQ AVLDVEPALG KRGFSRVDIA KIAGGGAQAL QAVLGLEPTL
RKRGFHPTDI IKIAGNNGGA QALQAVLDLE LMLRERGFSQ ADIVKMASNI GGAQALQAVL
NLEPALCERG FSQPDIVKMA GNSGGAQALQ AVLDLELAFR ERGFSQADIV KMASNIGGAQ
ALQAVLELEP ALHERGFSQA NIVKMAGNSG GAQALQAVLD LELVFRERGF SQPEIVEMAG
NIGGAQALHT VLDLELAFRE RGVRQADIVK IVGNNGGAQA LQAVFELEPT LRERGFNQAT
IVKIAANGGG AQALYSVLDV EPTLDKRGFS RVDIVKIAGG GAQALHTAFE LEPTLRKRGF
NPTDIVKIAG NKGGAQALQA VLELEPALRE RGFNQATIVK MAGNAGGAQA LYSVLDVEPA
LRERGFSQPE IVKIAGNIGG AQALHTVLEL EPTLHKRGFN PTDIVKIAGN SGGAQALQAV
LELEPAFRER GFGQPDIVKM ASNIGGAQAL QAVLELEPAL RERGFSQPDI VEMAGNIGGA
QALQAVLELE PAFRERGFSQ SDIVKIAGNI GGAQALQAVL ELEPTLRESD FRQADIVNIA
GNDGSTQALK AVIEHGPRLR QRGFNRASIV KIAGNSGGAQ ALQAVLKHGP TLDERGFNLT
NIVKIAGNGG GAQALKAVIE HGPTLQQRGF NLTDIVEMAG KGGGAQALKA VLEHGPTLRQ
RGFNLIDIVE MASNTGGAQA LKTVLEHGPT LRQRDLSLID IVEIASNGGA QALKAVLKYG
PVLMQAGRSN EEIVHVAARR GGAGRIRKMV ALLLERQ
